Evidence map›Paper›PMID 42878984›Full record

ArticleInternational journal of hematology2026

Temporal trends in transfusion-transmitted cytomegalovirus infection among cytomegalovirus-seronegative HSCT recipients.

Kimikazu Yakushijin, Takahiro Fukuda, Masao Ogata, Sachiko Seo, Ryu Yanagisawa, Michiko Kajiwara, Naoyuki Uchida, Youko Suehiro, Noriko Doki, Yoshinobu Kanda and 15 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Kimikazu YakushijinDivision of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan. kyakushi@med.kobe-u.ac.jp.ORCID http://orcid.org/0000-0003-2511-7857
Takahiro FukudaDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Masao OgataDepartment of Hematology, Oita University Hospital, Yufu, Japan.
Sachiko SeoDivision of Hematology, Department of Internal Medicine, Tokyo Women's Medical University, Tokyo, Japan.
Ryu YanagisawaDivision of Blood Transfusion, Shinshu University Hospital, Matsumoto, Japan.
Michiko KajiwaraCenter for Transfusion Medicine and Cell Therapy, Institute of Science Tokyo Hospital, Tokyo, Japan.
Naoyuki UchidaDepartment of Hematology, Federation of National Public Service Personnel Mutual Aid Associations TORANOMON HOSPITAL, Tokyo, Japan.
Youko SuehiroDepartment of Hematology and Cell Therapy, NHO Kyushu Cancer Center, Fukuoka, Japan.
Noriko DokiHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Yoshinobu KandaDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Masatsugu TanakaDepartment of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
Mineo KurokawaDepartment of Cell Therapy and Transplantation Medicine, The University of Tokyo Hospital, Tokyo, Japan.
Daiichiro HasegawaDepartment of Hematology and Oncology, Center of Childhood Cancer, Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan.
Motoshi IchikawaDepartment of Hematology, NTT Medical Center Tokyo, Tokyo, Japan.
Nobuhiro TsukadaDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Yoshiyuki TakahashiDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Satoshi YoshiharaDepartment of Hematology, Hyogo Medical University Hospital, Nishinomiya, Japan.
Satoshi OkadaDepartment of Pediatrics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.
Shinichi ItoDepartment of Hematology, Hakodate Municipal Hospital, Hakodate, Japan.
Shingo YanoDivision of Clinical Oncology and Hematology, The Jikei University School of Medicine, Tokyo, Japan.
Makoto OnizukaDepartment of Hematology/Oncology, Tokai University School of Medicine, Isehara, Japan.
Fumihiko IshimaruJapanese Red Cross Blood Service Headquarters, Tokyo, Japan.
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan.
Hideki NakasoneDivision of Emerging Medicine for Integrated Therapeutics, Center for Molecular Medicine, Jichi Medical University, Shimotsuke, Japan.
Transplant Complications Working Group. of the Japanese Society for Transplantation and Cellular Therapy (JSTCT)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe incidence of transfusion-transmitted cytomegalovirus (TT-CMV) after hematopoietic stem cell transplantation (HSCT) in the era of universal leukoreduction remains unclear. This study evaluated temporal changes in TT-CMV and clinically significant CMV infection (csCMVi) in Japan.

methodsData from 5,016 CMV-seronegative HSCT recipients registered between 1999 and 2022 were retrospectively analyzed. TT-CMV was defined as CMV antigenemia and/or CMV disease, and csCMVi as the initiation of pre-emptive therapy or CMV disease.

resultsRandom donor (RD) blood products were independently associated with TT-CMV (odds ratio 2.35, 95% confidence interval 1.75-3.15, P < 0.001) and csCMVi (subdistribution hazard ratio 2.22, 95% CI 1.67-2.96, P < 0.001). Among allogeneic HSCT recipients receiving RD blood products, TT-CMV decreased from 25.7% in 2007-2020 to 12.7% in 2021-2022, while the 100-day cumulative incidence of csCMVi decreased from 24.7% to 8.3% over the same periods. During 2021-2022, differences between RD and CMV-seronegative donor blood products were not statistically significant. CMV disease incidence did not differ between groups.

conclusionsTT-CMV and csCMVi decreased substantially over time. Although RD blood products remained associated with higher overall risk, the additional benefit of CMV-seronegative blood products may be limited under contemporary transfusion practices.

Indexed as

Cytomegalovirus-seronegative recipientsDonor blood productsHematopoietic stem cell transplantationRetrospective analysisTransfusion-transmitted cytomegalovirus

Identifiers

PMID42878984

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.